MAY 06, 2020 10:32 AM PDT

Why Doctors are Repurposing Drugs to Treat COVID-19

WRITTEN BY: Annie Lennon

Creating a drug from scratch is a lengthy process. Often taking years, given the rate of infection and deadliness of COVID-19, researchers do not have time to create new treatments. Thus, more often than not, they repurpose existing drugs already used against other diseases. 

This is not a new practice. In fact, in most countries, doctors are free to prescribe drugs for new and rare conditions should no other treatment exist either due to their novelty or a lack of profitability by pharmaceutical companies. Whether these drugs were then effective in their repurposed plight was as much up to trial and error as it was chance. 

Although commonly used in the past, doctors and researchers nowadays have more sophisticated testing techniques than trial and error and crossing fingers. Rather than simply ‘hoping for the best’, today researchers employ network analysis and artificial intelligences to narrow down the screening process to more effectively identify drug candidates. Although able to accelerate the process, it is still not able to fully replace human testing. 

This is why hundreds of clinical trials are currently underway to decipher which drugs may be most effective against COVID-19. However, due to the urgency of the situation, many argue that insufficient data is being collected to truly determine the efficacy of drugs. 

A good example of this is the recent clinical trial on Gilead’s remdesivir reporting that the drug is able to reduce recovery times from COVID-19 from 15 days to 11. Although received with optimism, another study from China found no statistically significant link between the treatment and recovery times. Although a smaller trial in which most patients were treated later on in their illness, as no little other clinical evidence exists on the drug, some may be cautious on exactly how effective it is. 

However, given that large, randomized, placebo-controlled trials are challenging and expensive to run, it may take some time until the real efficacy of the drugs currently used to treat COVID-19 are revealed. Until then, doctors and researchers alike will continue to make quick decisions about how best to treat their patients using the limited evidence they have on existing drugs.

 

Sources: Wired, LabRoots, New York Times

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
APR 06, 2020
Cancer
APR 06, 2020
A New Lead in the Treatment of Hepatocellular Carcinomas
  Hepatocellular carcinoma, or HCC, is a type of liver cancer, and the third most prevalent cancer-caused death in ...
APR 04, 2020
Cancer
APR 04, 2020
Unique Cancer Mutation Hijacks Nearby Signaling Pathway
  In cancer, tyrosine kinase mutations are quite common. MET is one such example that normally binds its native lig ...
MAR 31, 2020
Microbiology
MAR 31, 2020
Researchers Suggest Repurposing Pancreatitis Drug to Treat COVID-19
As SARS-CoV-2 upends normalcy in the world, researchers are trying to find a treatment for the illness it causes.
APR 23, 2020
Drug Discovery & Development
APR 23, 2020
Over 200 Volunteers Design $216 Ventilator for COVID-19
Over 200 volunteers from France have designed a ventilator suitable to treat COVID-19 patients that costs less than $500 ...
APR 21, 2020
Health & Medicine
APR 21, 2020
How to Read COVID-19 News (Without Going Crazy)
  It can feel like COVID-19 news is consuming the country, and taking all the toilet paper and N95-masks with it. N ...
MAY 21, 2020
Cancer
MAY 21, 2020
A New Player in the Regulation of Cancer's Microenvironment
Breast cancer is one of the most common cancers in the world.  Triple-negative breast cancer (TNBC) is a sub-type o ...
Loading Comments...